Evoq Remedies Ltd (543500)
Latest quarterly results (H2 FY26)
In its latest reported quarter, H2 FY26, Evoq Remedies' revenue was ₹0.0 Cr (-100.0% year on year, -100.0% on the previous half-year), and net profit ₹-0.3 Cr (against a profit a year earlier).
| H2 FY26 (₹ Cr) | Value | YoY vs H2 FY25 | vs prev. half |
|---|---|---|---|
| Revenue | ₹0.0 | -100.0% | -100.0% |
| Operating profit | ₹-0.5 | loss narrowed | loss narrowed |
| Net profit | ₹-0.3 | to loss | to loss |
| EPS (₹) | -0.12 | to loss | to loss |
📢 Recent Corporate Announcements
Evoq Remedies Limited has received approval from the Registrar of Companies (ROC Ahmedabad) for a 1-month extension to conduct its 16th Annual General Meeting (AGM) for FY26. The due date, originally September 30, 2026, has been extended to October 30, 2026. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code, 2016. The application had originally requested an extension up to December 17, 2026, but the ROC granted only 30 days.
- ROC Ahmedabad granted an extension of 1 month under Section 96(1) of the Companies Act, 2013
- AGM due date moved from 30th September, 2026 to 30th October, 2026
- Company had requested extension up to 17th December, 2026 via application dated 28th September, 2026
- Company is currently undergoing Corporate Insolvency Resolution Process (CIRP) managed by the Resolution Professional
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
